Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 12	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 17	JUL 28	CA/CAplus patent coverage enhanced
NEWS 18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20	JUL 28	STN Viewer performance improved
NEWS 21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 24	AUG 15	CAplus currency for Korean patents enhanced
NEWS 25	AUG 25	CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 27	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 28	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances

```
 NEWS 29  SEP 26  WPIDS, WPINDEX, and WPIX coverage of Chinese and
                  and Korean patents enhanced
 NEWS 30  SEP 29  IFICLS enhanced with new super search field
 NEWS 31  SEP 29  EMBASE and EMBAL enhanced with new search and
                  display fields

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:09:27 ON 29 SEP 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.42       0.42

FILE 'REGISTRY' ENTERED AT 12:10:27 ON 29 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 SEP 2008  HIGHEST RN 1053621-88-7
DICTIONARY FILE UPDATES:  26 SEP 2008  HIGHEST RN 1053621-88-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10590026s3.str
```



chain nodes :
8 9 10 11
ring nodes :
1 2 3 4 5 6 7 12 13 14 15 16
chain bonds :
6-8 7-9 8-10 9-10 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-16 12-13 13-14 14-15 15-16
exact/norm bonds :
6-8 7-9 8-10 9-10 10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-16 12-13 13-14 14-15 15-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom

L1 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\STNEXP\Queries\10590026s2.str



chain nodes :
13 14 15 16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 17 18 19 20
chain bonds :
6-13 8-14 13-15 14-15 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 7-20 8-9 9-10 10-11 11-12 12-17
17-18 18-19 19-20
exact/norm bonds :
6-13 8-14 13-15 14-15 15-16

```
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  7-20  8-9  9-10  10-11  11-12  12-17
17-18  18-19  19-20


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:Atom  18:Atom  19:Atom
 20:Atom



L2      STRUCTURE UPLOADED

=> s l1 sss sam and l2 sss sam
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms.  L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles.  The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> s l1 and l2 sss sam
SAMPLE SEARCH INITIATED 12:11:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      664 TO ITERATE

100.0% PROCESSED      664 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        11734 TO    14826
PROJECTED ANSWERS:            2266 TO     3734

L3           50 SEA SSS SAM L1 AND L2

=> s l1 and l2 sss full
FULL SEARCH INITIATED 12:12:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    12990 TO ITERATE

100.0% PROCESSED    12990 ITERATIONS                         2738 ANSWERS
SEARCH TIME: 00.00.01

L4         2738 SEA SSS FUL L1 AND L2

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               179.28     179.70

FILE 'CAPLUS' ENTERED AT 12:12:12 ON 29 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
```

FILE COVERS 1907 - 29 Sep 2008 VOL 149 ISS 14
FILE LAST UPDATED: 28 Sep 2008 (20080928/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l4
L5         542 L4

=> s l4 and raf
           542 L4
          8165 RAF
           102 RAFS
          8241 RAF
                 (RAF OR RAFS)
L6           5 L4 AND RAF

=> d ibib abs hitstr l6 1-5
```

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:353197 CAPLUS
DOCUMENT NUMBER: 148:355817
TITLE: Preparation of heterocyclic ureas as kinase inhibitors useful for the treatment of proliferative diseases
INVENTOR(S): Flynn, Daniel L.; Petillo, Peter A.; Kaufman, Michael D.; Patt, William C.
PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, LLC, USA
SOURCE: PCT Int. Appl., 167pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008033999	A2	20080320	WO 2007-US78394	20070913
WO 2008033999	A3	20080807		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-844552P P 20060914
US 2007-854293 A 20070912

OTHER SOURCE(S): MARPAT 148:355817

GI



I



II

AB The present invention relates to novel kinase inhibitors and modulators of general formula I (wherein X-Y is C=N or N-CH2; E1 is cyclopropyl, furyl, Ph, etc.; A is Ph, naphthyl, indanyl, etc.; Z6 is H, C1-C6alkyl, branched C3-C7alkyl, etc.; R3 and R16 are H, C1-C6 alkyl, branched C3-C7alkyl, etc.; R4 is H, C1-C6alkyl, hydroxyC1-C6alkyl, etc.; X2 is a direct bond or (un)branched C1-C6 alkyl; t is 1-3) useful for the treatment of various diseases. More particularly, the invention is concerned with such compds., kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compds. Preferably, the compds. are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compds. of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compds. of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration. Example compound II was prepared by reacting 7-amino-3-(3-amino-4-fluorophenyl)-1-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (preparation given) and prop-1-en-2-yl 3-tert-butyl-1-phenyl-1H-pyrazol-5-ylcarbamate (preparation given). In general, the I tested exhibited >50 % inhibition activity at 0.2-2 μM concentration in V600E B- Raf kinase and C-Raf kinase assays. In general, the I tested exhibited >50 % inhibition of proliferation at 1-10uM concentration against A375 cells.

IT 1011463-01-6P, 1-[5-[1-Ethyl-7-(methylamino)-2-oxo-1,2-dihydropyrido[4,3-d]pyrimidin-3(4H)-yl]-2-fluoro-4-methylphenyl]-3-(naphthalen-1-yl)urea 1011463-02-7P, 1-[5-[1-Ethyl-7-(methylamino)-2-oxo-1,2-dihydropyrido[4,3-d]pyrimidin-3(4H)-yl]-2-fluorophenyl]-3-(naphthalen-1-yl)urea 1011463-03-8P, 1-[4-Chloro-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydropyrido[4,3-d]pyrimidin-3(4H)-yl]-2-fluorophenyl]-3-(naphthalen-1-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(drug candidate; preparation of heterocyclic ureas as kinase inhibitors useful for treatment of proliferative diseases)

RN 1011463-01-6 CAPLUS
CN Urea, N-[5-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrido[4,3-d]pyrimidin-3(2H)-yl]-2-fluoro-4-methylphenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1011463-02-7 CAPLUS
CN Urea, N-[5-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrido[4,3-d]pyrimidin-3(2H)-yl]-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1011463-03-8 CAPLUS
CN Urea, N-[4-chloro-5-[1-ethyl-1,4-dihydro-7-(methylamino)-2-oxopyrido[4,3-d]pyrimidin-3(2H)-yl]-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:353037 CAPLUS
DOCUMENT NUMBER: 148:379650
TITLE: Preparation of heterocyclic ureas as kinase inhibitors useful for the treatment of proliferative and inflammatory diseases

INVENTOR(S): Flynn, Daniel L.; Kaufman, Michael D.; Patt, William C.; Petillo, Peter A.
PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, Llc., USA
SOURCE: PCT Int. Appl., 298pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008034008	A2	20080320	WO 2007-US78408	20070913
WO 2008034008	A3	20080710		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20080114006	A1	20080515	US 2007-854354	20070912
PRIORITY APPLN. INFO.:			US 2006-844552P P	20060914
			US 2007-854354 A	20070912

OTHER SOURCE(S): MARPAT 148:379650
GI



I



II

AB The present invention relates to novel kinase inhibitors and modulators of general formula I (wherein E1 is cyclopropyl, furyl, Ph, etc.; A is Ph,

naphthyl, indanyl, etc.; Z6 is H, C1-C6alkyl, branched C3-C7alkyl, etc.; R3 and R16 are H, C1-C6 alkyl, branched C3-C7alkyl, etc.; R4 is H, C1-C6alkyl, hydroxyC1-C6alkyl, etc.; X2 is a direct bond or (un)branched C1-C6 alkyl; t is 1-3) useful for the treatment of various diseases. More particularly, the invention is concerned with such compds., kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compds. Preferably, the compds. are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compds. of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compds. of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration. Example compound II was prepared by reacting 2-amino-6-(3-amino-4-fluorophenyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (preparation given) and 3-tert-butyl-1-phenyl-1H-pyrazol-5-amine (preparation given). In general, the I tested exhibited >50 % inhibition activity at 0.2-2 μM concentration in V600E B- Raf kinase and C-Raf kinase assays. In general, the I tested exhibited >50 % inhibition of proliferation at 1-10uM concentration against A375 cells.

IT 1012873-31-2P, 1-[5-(2-Amino-8-ethyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl]-3-(naphthalen-1-yl)urea 1012874-63-3P, 1-[2-Fluoro-4-methyl-5-[8-methyl-2-(methylamino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]phenyl]-3-(naphthalen-1-yl)urea 1012874-98-4P, 1-[5-(2-Amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluoro-4-methylphenyl]-3-(4-bromonaphthalen-1-yl)urea 1012874-99-5P, 1-[5-(2-Amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluoro-4-methylphenyl]-3-(4-chloronaphthalen-1-yl)urea 1012875-02-3P, 1-[5-[2-[[2-(Dimethylamino)ethyl]amino]-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]-2-fluorophenyl]-3-(naphthalen-1-yl)urea 1012875-23-8P, 1-[5-(2-Amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl]-3-(naphthalen-1-yl)urea 1012875-98-7P, 1-[2-Fluoro-5-[8-isopropyl-2-(methylamino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]phenyl]-3-(naphthalen-1-yl)urea 1012877-09-6P 1012877-18-7P 1012877-21-2P 1012877-30-3P 1012877-48-3P 1012880-45-3P, 1-[5-(2-Amino-8-ethyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl]-3-(naphthalen-1-yl)urea hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocyclic ureas as kinase inhibitors useful for the treatment of proliferative and inflammatory diseases)

RN 1012873-31-2 CAPLUS

CN Urea, N-[5-(2-amino-8-ethyl-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012874-63-3 CAPLUS
CN Urea, N-[5-[7,8-dihydro-8-methyl-2-(methylamino)-7-oxopyrido[2,3-d]pyrimidin-6-yl]-2-fluoro-4-methylphenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012874-98-4 CAPLUS
CN Urea, N-[5-(2-amino-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-6-yl)-2-fluoro-4-methylphenyl]-N'-(4-bromo-1-naphthalenyl)- (CA INDEX NAME)



RN 1012874-99-5 CAPLUS
CN Urea, N-[5-(2-amino-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-6-yl)-2-fluoro-4-methylphenyl]-N'-(4-chloro-1-naphthalenyl)- (CA INDEX NAME)



RN 1012875-02-3 CAPLUS
CN Urea, N-[5-[2-[[2-(dimethylamino)ethyl]amino]-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-6-yl]-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012875-23-8 CAPLUS
CN Urea, N-[5-(2-amino-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012875-98-7 CAPLUS
CN Urea, N-[5-[7,8-dihydro-2-(methylamino)-8-(1-methylethyl)-7-oxopyrido[2,3-d]pyrimidin-6-yl]-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012877-09-6 CAPLUS
CN Urea, N-[5-(1-ethyl-1,2-dihydro-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012877-18-7 CAPLUS
CN Urea, N-[5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluoro-4-methylphenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012877-21-2 CAPLUS
CN Urea, N-[5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012877-30-3 CAPLUS
CN Urea, N-[4-chloro-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012877-48-3 CAPLUS
CN Urea, N-[4-chloro-5-[1,2-dihydro-1-methyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 1012880-45-3 CAPLUS
CN Urea, N-[5-(2-amino-8-ethyl-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl]-N'-1-naphthalenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 1012882-99-3P, 1-[2-Fluoro-5-[8-methyl-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]phenyl]-3-(naphthalen-1-yl)urea
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic ureas as kinase inhibitors useful for the treatment of proliferative and inflammatory diseases)
RN 1012882-99-3 CAPLUS
CN Urea, N-[5-[7,8-dihydro-8-methyl-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-6-yl]-2-fluorophenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:381061 CAPLUS
DOCUMENT NUMBER: 144:412508
TITLE: Preparation of imidazo[4,5-b]pyridin-2-ones and

oxazolo[4,5-b]pyridin-2-ones as inhibitors of RAF kinase

INVENTOR(S): Niculescu-Duvaz, Dan; Springer, Caroline Joy; Gill, Adrian Liam; Taylor, Richard David; Marais, Richard Malcolm; Dijkstra, Harmen; Gaulon, Catherine; Menard, Delphine; Roman Vela, Esteban

PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK; Institute of Cancer Research Royal Cancer Hospital; Astex Therapeutics Limited

SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006043090	A1	20060427	WO 2005-GB4081	20051021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005297089	A1	20060427	AU 2005-297089	20051021
CA 2584651	A1	20060427	CA 2005-2584651	20051021
EP 1812433	A1	20070801	EP 2005-796691	20051021
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101084217	A	20071205	CN 2005-80043991	20051021
JP 2008517890	T	20080529	JP 2007-537390	20051021
BR 2005016234	A	20080826	BR 2005-16234	20051021
IN 2007KN01693	A	20070727	IN 2007-KN1693	20070514
NO 2007002546	A	20070723	NO 2007-2546	20070518
US 20070287838	A1	20071213	US 2007-665640	20070808

PRIORITY APPLN. INFO.:

GB 2004-23554	A	20041022
US 2004-620658P	P	20041022
WO 2005-GB4081	W	20051021

OTHER SOURCE(S): MARPAT 144:412508

GI



I

AB Title compds. [I; J = O, NRn1; Rn1, Rn2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl; Y = CH, N; Q = (CH2)jM(CH2)k; j, k = 0-2; j+k = 0-2; M = O, S, NH, NMe, CH2; R1-R4 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, haloalkyl, acyl; R1R2 = CH:CHCH:CH; L = linker formed by a chain of 2-4 specified linker moieties; A = aryl, heteroaryl, carbocyclyl, heterocyclyl], were prepared Thus, 4-chloro-3-trifluoromethylphenyl isothiocyanate and 7-(4-aminophenoxy)-1H-imidazo[4,5-b]pyridin-2(3H)-one were stirred together for 3 days in THF to give 1-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl]-3-(4-chloro-3-trifluoromethylphenyl)thiourea. In a BRAF V600E kinase inhibition assay, ≥3 I had IC50's of <0.01 μM.

IT 884339-11-1P 884339-12-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridinones and oxazolopyridinones as inhibitors of RAF kinase)

RN 884339-11-1 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)oxy]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 884339-12-2 CAPLUS
CN Urea, N-[4-[(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7-yl)oxy]-1-

naphthalenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:656575 CAPLUS
DOCUMENT NUMBER: 139:197476
TITLE: Preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity
INVENTOR(S): Dumas, Jacques; Scott, William J.; Elting, James; Hatoum-Makdad, Holia
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003068223	A1	20030821	WO 2003-US4102		20030211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2003210969	A1	20030904	AU 2003-210969		20030211
US 20040023961	A1	20040205	US 2003-361844		20030211
PRIORITY APPLN. INFO.:			US 2002-354948P	P	20020211
			WO 2003-US4102	W	20030211

GI



I

AB 283 Of the title ureas useful for treating diseases mediated by raf kinase and diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes, were claimed. Synthesis of 6 ureas such as I was described. Thus, reacting 3-(tert-butyl)-1-(4-methylphenyl)pyrazole-5-ylamine with 4-(2-morpholin-4-ylethoxy)naphthylamine (prepns. given) and CDI in CH2Cl2 afforded 80% I which showed IC50 of < 1 μM in in vitro raf kinase and in in vitro Flk-1 ELISA assay.

IT 294849-72-2P 294849-74-4P 294849-76-6P
294849-78-8P 294849-80-2P 294849-82-4P
294849-84-6P 294849-86-8P 294849-88-0P
294849-92-6P 294849-94-8P 294849-97-1P
294850-00-3P 294850-02-5P 294850-04-7P
294850-06-9P 294850-09-2P 294850-12-7P
294850-15-0P 294850-18-3P 294850-21-8P
294850-24-1P 294850-27-4P 294850-29-6P
294850-31-0P 294850-33-2P 294850-35-4P
294850-37-6P 294850-39-8P 294850-41-2P
294850-43-4P 294850-45-6P 294850-47-8P
294850-49-0P 294850-51-4P 294850-53-6P
294850-55-8P 294850-57-0P 294850-59-2P
294850-61-6P 294850-63-8P 294850-65-0P
294850-67-2P 294850-69-4P 294850-71-8P
294850-73-0P 294850-76-3P 294850-79-6P
294850-81-0P 294850-84-3P 294850-87-6P
294850-90-1P 294850-93-4P 294850-96-7P
294851-02-8P 294851-05-1P 294851-07-3P
294851-09-5P 294851-11-9P 294851-14-2P
294851-18-6P 294851-20-0P 294851-22-2P
294851-24-4P 294851-26-6P 294851-28-8P
294851-32-4P 294851-34-6P 294851-36-8P
294851-38-0P 294851-40-4P 294851-42-6P
294851-44-8P 294851-46-0P 294851-48-2P
294851-50-6P 294851-52-8P 294851-56-2P
294851-58-4P 294851-60-8P 294851-62-0P
294851-64-2P 294851-66-4P 294851-68-6P
294851-70-0P 294851-72-2P 294851-76-6P
294855-56-4P 340825-40-3P 340825-41-4P
340825-46-9P 340825-47-0P 340825-48-1P
340825-49-2P 340825-51-6P 340825-52-7P
340825-53-8P 340825-54-9P 340825-55-0P
340825-56-1P 501365-69-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

RN 294849-72-2 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-74-4 CAPLUS

CN Urea, N-(4-methyl[1,1'-biphenyl]-3-yl)-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-76-6 CAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)[1,1'-biphenyl]-2-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-78-8 CAPLUS
CN Urea, N-[2-methyl-5-(1-methylethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-80-2 CAPLUS
CN Urea, N-[2-methoxy-5-(1-methylpropyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-82-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(methoxymethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-84-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-86-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 294849-88-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-92-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylpropyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-94-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(1H-pyrazol-4-yl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294849-97-1 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(2-methyl-5-pyrimidinyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-00-3 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(3-hydroxypropyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-02-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(4-morpholinylcarbonyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-04-7 CAPLUS
CN Acetamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-06-9 CAPLUS
CN Urea, N-(3-methyl-2-naphthalenyl)-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 294850-09-2 CAPLUS
CN Urea, N-[3-(2,3-dihydroxypropyl)-5-(1,1-dimethylethyl)-2-hydroxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)





RN 294850-12-7 CAPLUS
CN Urea, N-(2,3-dimethyl-1H-indol-5-yl)-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 294850-15-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methyl-3-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-propyn-1-yl]phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-18-3 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-21-8 CAPLUS
CN Urea, N-[5-(2,2-dimethyl-1-oxopropyl)-2-methylphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-24-1 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-(3-hydroxy-1-propyn-1-yl)-2-methylphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-27-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(3-hydroxy-1-propyn-1-yl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-29-6 CAPLUS
CN Urea, N-[3-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-31-0 CAPLUS
CN Urea, N-[3-(2,3-dihydroxypropyl)-5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-33-2 CAPLUS
CN Urea, N-[5-(1,1-dimethylethoxy)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-35-4 CAPLUS
CN Urea, N-[5-(1-cyanocyclopropyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-37-6 CAPLUS
CN Urea, N-[3-[2-(diethylamino)ethyl]-5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-39-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(1,3-dioxolan-2-yl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 294850-41-2 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(1-pyrrolidinyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-43-4 CAPLUS
CN Urea, N-[2-(dimethylamino)-5-(1,1-dimethylethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-45-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-propoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-47-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(hydroxymethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 294850-49-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[(2,6-dimethyl-4-morpholinyl)methyl]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-51-4 CAPLUS
CN Urea, N-(5-cyclohexyl-2-methoxyphenyl)-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-53-6 CAPLUS
CN Urea, N-[2,4-dimethoxy-5-(trifluoromethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-55-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxy-3-nitrophenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-57-0 CAPLUS
CN Urea, N-[3-amino-5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-(6-methyl-3-pyridinyl)-1-naphthalenyl]- (CA INDEX NAME)



RN 294850-59-2 CAPLUS
CN Acetamide, N-acetyl-N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)





RN 294850-61-6 CAPLUS
CN Urea, N-[6-(1,1-dimethylethyl)-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazin-8-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 294850-63-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-ethoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-65-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(1-methylethoxy)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-67-2 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(1H-imidazol-1-yl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-69-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-(ethylamino)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-71-8 CAPLUS
CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-N-(methylsulfonyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-73-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(1-methyl-1H-pyrazol-4-yl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-76-3 CAPLUS
CN Urea, N-[2-(methylsulfinyl)-5-(trifluoromethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-79-6 CAPLUS
CN Urea, N-[4-[6-[[bis(2-methoxyethyl)amino]methyl]-3-pyridinyl]-1-naphthalenyl]-N'-[5-(1,1-dimethylethyl)-2-methoxyphenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-81-0 CAPLUS
CN Acetamide, N-[1-[[5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]-1-naphthalenyl]-2-pyridinyl]methyl]-3-pyrrolidinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-84-3 CAPLUS
CN Urea, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-5-yl)-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 294850-87-6 CAPLUS
CN Propanamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



PAGE 2-A



RN 294850-90-1 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methyl-7-benzoxazolyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-93-4 CAPLUS
CN Urea, N-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]-N'-[3-[(trifluoromethyl)sulfonyl]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294850-96-7 CAPLUS
CN Propanamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-02-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2,3-dihydro-2-oxo-7-benzoxazolyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-05-1 CAPLUS
CN Urea, N-[3-cyano-5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-07-3 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-7-benzoxazolyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-09-5 CAPLUS
CN Benzenesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-11-9 CAPLUS
CN Ethanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-14-2 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(methylthio)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-18-6 CAPLUS
CN Ethanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-20-0 CAPLUS
CN Methanesulfonamide, N-[5-[4-[[[[5-(1,1-dimethylethyl)-2-methylphenyl]amino]carbonyl]amino]-1-naphthalenyl]-2-pyrazinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 294851-22-2 CAPLUS
CN Urea, N-[4-[6-[[bis(2-cyanoethyl)amino]methyl]-3-pyridinyl]-1-naphthalenyl]-N'-[5-(1,1-dimethylethyl)-2-methoxyphenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-24-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[(4-methyl-1-piperazinyl)methyl]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-26-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-thiomorpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-28-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[(2,6-dimethyl-1-piperidinyl)methyl]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-32-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[(tetrahydro-2H-pyran-4-yl)amino]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-34-6 CAPLUS
CN Urea, N-[4-[6-[[(2-cyanoethyl)[(tetrahydro-2-furanyl)methyl]amino]methyl]-3-pyridinyl]-1-naphthalenyl]-N'-[5-(1,1-dimethylethyl)-2-methoxyphenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-36-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[[2-(methoxymethyl)-4-morpholinyl]methyl]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-38-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[(2-methyl-3-oxo-1-piperazinyl)methyl]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-40-4 CAPLUS
CN 3-Piperidinecarboxamide, 1-[[5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]-1-naphthalenyl]-2-pyridinyl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-42-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[(1-oxido-4-thiomorpholinyl)methyl]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-44-8 CAPLUS
CN Urea, N-(2,3-dihydro-3,3-dimethyl-2-oxo-1H-indol-5-yl)-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 294851-46-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[(3-oxo-1-piperazinyl)methyl]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-48-2 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[[(tetrahydro-3-furanyl)amino]methyl]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-50-6 CAPLUS
CN Urea, N-[4-[6-[[(2-cyanoethyl)(3-pyridinylmethyl)amino]methyl]-3-pyridinyl]-1-naphthalenyl]-N'-[5-(1,1-dimethylethyl)-2-methoxyphenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-52-8 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-56-2 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-[[4-(3-methoxyphenyl)-1-piperazinyl]methyl]-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-58-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylcarbonyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-60-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[5-(4-morpholinylmethyl)-2-pyrazinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-62-0 CAPLUS
CN Urea, N-[6-(1,1-dimethylethyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-8-yl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 294851-64-2 CAPLUS
CN Urea, N-[3-amino-5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)





RN 294851-66-4 CAPLUS
CN Acetamide, N-[5-[4-[[[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]carbonyl]amino]-1-naphthalenyl]-2-pyridinyl]- (CA INDEX NAME)



RN 294851-68-6 CAPLUS
CN Acetamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-N-methyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-70-0 CAPLUS
CN Acetamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-72-2 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[6-(3-pyridinyloxy)-3-pyridinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294851-76-6 CAPLUS
CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 294855-56-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[2-(4-morpholinylmethyl)-5-pyrimidinyl]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 340825-40-3 CAPLUS
CN Urea, N-[4-[(2-amino-4-pyridinyl)oxy]-1-naphthalenyl]-N'-[5-(1,1-dimethylethyl)-2-methylphenyl]- (CA INDEX NAME)



RN 340825-41-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-(4-morpholinyl)phenyl]-N'-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)





RN 340825-46-9 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[(2-methoxy-4-pyridinyl)oxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 340825-47-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[(2-methyl-4-pyridinyl)oxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 340825-48-1 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2,3-dimethoxyphenyl]-N'-[4-[(2-methoxy-4-pyridinyl)oxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 340825-49-2 CAPLUS
CN Benzamide, 5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-(4-pyridinyloxy)-1-naphthalenyl]amino]carbonyl]amino]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 340825-51-6 CAPLUS
CN 4-Morpholinecarboxamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-(4-pyridinyloxy)-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 340825-52-7 CAPLUS
CN Acetamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-(4-pyridinyloxy)-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 340825-53-8 CAPLUS
CN Urea, N'-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-(4-pyridinyloxy)-1-naphthalenyl]amino]carbonyl]amino]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 340825-54-9 CAPLUS
CN Urea, N-[4-[(2-amino-4-pyridinyl)oxy]-1-naphthalenyl]-N'-[5-(1,1-dimethylethyl)-2,3-dimethoxyphenyl]- (CA INDEX NAME)



RN 340825-55-0 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2,3-dimethoxyphenyl]-N'-[4-[[2-(methylamino)-4-pyridinyl]oxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 340825-56-1 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-2,3-dimethoxyphenyl]-N'-[4-[[2-[(1-phenylethyl)amino]-4-pyridinyl]oxy]-1-naphthalenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Ph

RN 501365-69-1 CAPLUS
CN Acetamide, 2-[4-(1,1-dimethylethyl)-2-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:421642 CAPLUS
DOCUMENT NUMBER: 131:58658
TITLE: Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
INVENTOR(S): Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Rodriguez, Mareli; Wang, Ming
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932436	A1	19990701	WO 1998-US26081	19981222

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2315646	A1	19990701	CA 1998-2315646		19981222
AU 9919054	A	19990712	AU 1999-19054		19981222
AU 763024	B2	20030710			
EP 1049664	A1	20001108	EP 1998-963809		19981222
EP 1049664	B1	20050316			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200002616	T2	20001121	TR 2000-2616		19981222
TR 200100874	T2	20010621	TR 2001-874		19981222
HU 2000004437	A2	20010628	HU 2000-4437		19981222
JP 2001526258	T	20011218	JP 2000-525373		19981222
BR 9814375	A	20020521	BR 1998-14375		19981222
NZ 505843	A	20030630	NZ 1998-505843		19981222
EP 1449834	A2	20040825	EP 2003-26051		19981222
EP 1449834	A3	20041222			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
RU 2247109	C2	20050227	RU 2000-120165		19981222
AT 291011	T	20050415	AT 1998-963809		19981222
ES 2153809	T3	20050716	ES 1998-963809		19981222
PL 195808	B1	20071031	PL 1998-342078		19981222
NO 2000003230	A	20000821	NO 2000-3230		20000621
MX 2000PA06231	A	20020918	MX 2000-PA6231		20000622
IN 2000MN00150	A	20050715	IN 2000-MN150		20000704
BG 104599	A	20010330	BG 2000-104599		20000712
BG 64594	B1	20050831			
IN 2003MN00960	A	20050429	IN 2003-MN960		20031013
PRIORITY APPLN. INFO.:			US 1997-996344	A	19971222
			EP 1998-963809	A3	19981222
			WO 1998-US26081	W	19981222

OTHER SOURCE(S): MARPAT 131:58658

GI



II

AB The invention relates to the use of a group of aryl ureas ANHCONHB [I; A = certain (un)substituted Ph, pyridinyl, or thien-2-yl groups; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] in treating raf-mediated diseases, and pharmaceutical compns. for use in such therapy. A subset of I are novel and are claimed per se. Approx. 160 invention compds. and numerous intermediates were prepared For instance, reaction of tolyl isocyanate with 2-methoxy-5-(trifluoromethanesulfonyl)aniline in EtOAc gave title compound II. In an in

vitro raf kinase assay, all compds. displayed IC50 values between 1 nM and 10 μM.

IT 228399-62-0P 228400-96-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sym. and unsym. substituted di-Ph ureas with inhibitory effects on tumors mediated by raf kinase)

RN 228399-62-0 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-1-naphthalenyl- (CA INDEX NAME)



RN 228400-96-2 CAPLUS
CN Urea, N-(3-methoxy-2-naphthalenyl)-N'-1-naphthalenyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.29	210.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

STN INTERNATIONAL LOGOFF AT 12:14:37 ON 29 SEP 2008